From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated)

References

• Mammen E, Thomas W, Seegers W. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-a). Thromb Diath Haemorrh 1960;5:218–49
   Google Scholar
• Seegers W, Novoa E, Henry R, et al. Relationship of ‘new’ vitamin K-dependent protein C and ‘old’ autoprothombin II-A. Thrombosis Res 1976;8:552
   Web of Science ®Google Scholar
• Stenflo J, Fernlund P. Amino acid sequence of the heavy chain of bovine protein C. J Biol Chem 1982;257:12180–90
   PubMed Web of Science ®Google Scholar
• Fernlund P, Stenflo J. Amino acid sequence of the light chain of bovine protein C. J Biol Chem 1982;257:12170–9
   PubMed Web of Science ®Google Scholar
• Howey DC, Hartman DL. Preparation for trials of recombinant activated protein C in sepsis: a pharmacokinetic and dynamic study in healthy men and women. Chest 1997;112:89S
   Google Scholar
• Kalil AC, Coyle SM, Um JY, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004;21:222–9
   PubMed Web of Science ®Google Scholar
• Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051–9
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709
   PubMed Web of Science ®Google Scholar
• Lan KKG, De Mets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659–63
   Web of Science ®Google Scholar
• Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199–206
   PubMed Web of Science ®Google Scholar
• Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;33: 2266–77
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332–41
   PubMed Web of Science ®Google Scholar
• Smith KJ, Neal J, Winton EF, et al. Purpura fulminans and S. pneumoniae sepsis with severe acquired protein C deficiency successfully treated with recombinant human activated protein C. Thromb Haemost 1999;82S:738
   Google Scholar
• Peck CC, Wechsler J. Report of a workshop on confirmatory evidence to support a single clinical trial as a basis for new drug approval. Drug Inf J 2002:517–34
   Google Scholar
• Dhainaut JF, Yan SB, Joyce DE. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924–33
   Google Scholar
• Ely E, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12–9
   PubMed Web of Science ®Google Scholar
• Ely EW, Angus DC, Williams MD, et al. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003;37:187–95
   PubMed Web of Science ®Google Scholar
• Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003;37:50–8
   PubMed Web of Science ®Google Scholar
• Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004;32: S239–46
   PubMed Web of Science ®Google Scholar
• Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004;32:S223–8
   PubMed Web of Science ®Google Scholar
• Barie PS, Williams MD, McCollam JS, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212–20
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification. Crit Care Med 1985;13:818–29
   PubMed Web of Science ®Google Scholar
• Xigris (package insert), Indianapolis, IN, USA: Eli Lilly and Co, 2006
   Google Scholar
• Beale R, Wright TJ, Wong K, et al. Safety of drotrecogin alfa (activated) in adult patients with severe sepsis: Comparison of global ENHANCE to PROWESS. Chest 2003;124:102S–3
   Google Scholar
• Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;7:155–63
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large, multicenter, phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003;31: 2291–301
   PubMed Web of Science ®Google Scholar
• Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants n-acetylcysteine and procysteine in ARDS. Chest 1997;112:164–72
   PubMed Web of Science ®Google Scholar
• Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–8
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/ failure. Intensive Care Med 1996;22:707–10
   PubMed Web of Science ®Google Scholar
• Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834–40
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894–903
   PubMed Web of Science ®Google Scholar
• Miranda DR, de Rijk A, Schaufeli W. Simplified therapeutic intervention scoring system: the TISS-28 items – results from a multicenter study. Crit Care Med 1996;24:64–73
   PubMed Web of Science ®Google Scholar
• Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004;32:2207–18
   PubMed Web of Science ®Google Scholar
• Macias WL, Yan SB, Grinnell BW. The development of drotrecogin alfa (activated) for the treatment of severe sepsis. Int J Artif Organs 2004;27:360–70
   Google Scholar
• Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004;8:R82–90
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Yan SB, Margolis BD, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642–53
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Yan SB, Cariou A, et al. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002;30:S318–24
   PubMed Web of Science ®Google Scholar
• Kitching AR, Kong YZ, Ru Huang X, et al. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003;14:1487–95
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Reiter R, Knobl P, et al. Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003;102:2093–8
   PubMed Web of Science ®Google Scholar
• Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878–85
   PubMed Web of Science ®Google Scholar
• Levy H, Small D, Heiselman DE, et al. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Ann Pharmacother 2005;39:262–7
   PubMed Web of Science ®Google Scholar
• Pastores SM, Shaw A, Williams MD, et al. A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research. Bone Marrow Transplant 2005;36:721–24
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Naureckas E, Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003;75:899–901
   Google Scholar
• FDA approval letter. Available from http://www.fda.gov/cder/foi/appletter/2001/droteli112101L.pdf [Last accessed 12 June 2006]
   Google Scholar
• Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999;25:556–66
   PubMed Web of Science ®Google Scholar
• Chaudry IH. Sepsis: lessons learned in the last century and future directions. Arch Surg 1999;134:922–9
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Marin N, Cariou A. Perspectives in anti-inflammatory therapies in sepsis. Evolving concepts in sepsis and septic shock. Boston: Kluwer Academic, 2001
   Google Scholar
• Llewelyn M, Cohen J. Anti-endotoxin antibodies in sepsis: a critical evaluation. Sepsis 1999;3:39–45
   Google Scholar
• Sevransky JE, Natanson C. An analysis of clinical trials of mediator-specific antiinflammatory agents. Sepsis 1999;3:11–9
   Google Scholar
• Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207–14
   PubMed Web of Science ®Google Scholar
• Macias WL, Vallet B, Bernard GR, et al. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med 2004;32:2385–90
   PubMed Web of Science ®Google Scholar
• Deans KJ, Minneci PC, Banks SM, et al. Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 2004;32:2542–43
   PubMed Web of Science ®Google Scholar
• http://www.microvisionmedical.com/modules.php?op=modload&name=News&file=article&sid=2&hmenu=Tech... – 9k – Supplemental Result [Last accessed 12 Jun 2006]
   Google Scholar
• Xigris (EU summary of product characteristics). Indianapolis, IN, USA: Eli Lilly and Co, 2006
   Google Scholar